Quinpirole

Synonyms: LY 171555; (-)-LY 141865
Quinpirole (LY 171555; (-)-LY 141865) 是一种 D2/D3 型多巴胺受体 (Dopamine Receptor) 激活剂和 CaV1.3 钙通道调节剂,可使多巴胺耗竭纹状体中的树突棘密度恢复正常,上调 BCL2 和 GluR2 的蛋白表达,下调 BAX 的蛋白表达,还可延迟癫痫发作起始时间;它能够增强学习与记忆能力,抑制神经元凋亡 (apoptosis),并可诱发焦虑样、刻板性和强迫性行为;此外,Quinpirole 会破坏恒河猴的前脉冲抑制,增强丘脑室旁核神经元的活动以促进 Isoflurane 麻醉后的苏醒,还能改变大鼠肠道菌群的组成,可用于异动症、疼痛、癫痫,以及包括焦虑症、强迫症、精神分裂症在内的神经系统疾病的相关研究。
产品编号: MS-A95956 纯度: 98.95% CAS No.: 80373-22-4 分子式: C13H21N3 分子量: 219.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Quinpirole (LY 171555; (-)-LY 141865) 是一种 D2/D3 型多巴胺受体 (Dopamine Receptor) 激活剂和 CaV1.3 钙通道调节剂,可使多巴胺耗竭纹状体中的树突棘密度恢复正常,上调 BCL2 和 GluR2 的蛋白表达,下调 BAX 的蛋白表达,还可延迟癫痫发作起始时间;它能够增强学习与记忆能力,抑制神经元凋亡 (apoptosis),并可诱发焦虑样、刻板性和强迫性行为;此外,Quinpirole 会破坏恒河猴的前脉冲抑制,增强丘脑室旁核神经元的活动以促进 Isoflurane 麻醉后的苏醒,还能改变大鼠肠道菌群的组成,可用于异动症、疼痛、癫痫,以及包括焦虑症、强迫症、精神分裂症在内的神经系统疾病的相关研究。

生物实验数据

生物活性 Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor (Dopamine Receptor) agonist and CaV1.3 calcium channel modulator that restores dendritic spine density in dopamine-depleted striatum, upregulates BCL2 and GluR2 protein expression, downregulates BAX protein expression, and delays seizure onset; it enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and can induce anxiety-like, stereotyped, and compulsive behaviors; furthermore, Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances paraventricular thalamic nucleus neuronal activity to promote emergence from Isoflurane anesthesia, and alters gut microbiota composition in rats, and it can be used for research on dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorders, obsessive-compulsive disorder, and schizophrenia.
体外研究
(In Vitro)

Quinpirole 可选择性抑制多巴胺耗竭大鼠纹状体中型多棘神经元中的高电压激活钙通道,该效应依赖于 L 型钙通道的活性。

体内研究
(In Vivo)

Quinpirole (0.05-0.1 mg/kg;皮下注射;每日 2 次;持续 4 周) 可持续且显著地抑制 Levodopa (MS-R94530) 诱导的异动症,并预防帕金森病大鼠多巴胺耗竭纹状体中异常蘑菇状树突棘的形成。
Quinpirole (0.1-3 mg/kg;皮下注射) 在未处理雄性 Wistar 大鼠、完全弗氏佐剂 (CFA) 诱导炎性疼痛模型、CCI 诱导的神经性疼痛中的机械伤害感受试验中可产生显著的镇痛作用,产生显著的伤害感受增强作用。
Quinpirole (侧脑室注射;单剂量;Pilocarpine 注射前 60 分钟) 对Lithium chloride (MS-D56483)-Pilocarpine (MS-U99376) 诱导的癫痫 Wistar 大鼠具有神经保护作用,可延迟癫痫发作起始、改善认知功能,并调控海马组织中 GluR2、BAX 及 BCL2 的蛋白表达。
Quinpirole (0.01-3 mg/kg,腹腔注射,处死前 1-4 小时) 可呈剂量依赖性降低大鼠下丘脑肾上腺素及大脑半球多巴胺代谢物的浓度;高剂量时还会改变下丘脑多巴胺、去甲肾上腺素以及脑干 MHPG 硫酸盐的浓度。
Quinpirole (5.5-50 μM; immersion; single 24-hour exposure; at 5 dpf) 可诱导成年斑马鱼出现持续性焦虑样行为、刻板游动及厌恶记忆损伤,而对其社交或攻击行为无影响。
Quinpirole (7-70 nM;向伏隔核核心双侧脑内输注;0.2 μl/min) 会破坏听觉惊跳反射的前脉冲抑制。
Quinpirole (0.5 mg/kg,皮下注射,每周 2 次,持续 5 周) 可在成年雄性 Wistar 大鼠中诱导类强迫症行为、神经炎症改变、肠道组织学变化、粪便短链脂肪酸水平降低及肠道菌群失调。
Quinpirole (4 mM,经丘脑室旁核微注射,总容积 0.5 μl,给药时长 2 分钟) 可显著缩短雄性 C57BL/6J 小鼠从 Isoflurane (MS-I85200) 麻醉中的苏醒时间、降低皮层爆发抑制比,并增强丘脑室旁核神经元活性。

Animal Model: Sprague-Dawley (adult male, 250g, unilateral stereotaxic injection of 6-hydroxydopamine hydrobromide to induce Parkinson's disease)
Dosage: 0.1 mg/kg (first 12 days); 0.05 mg/kg (remainder of experiment)
Administration: s.c.; twice daily; 4 weeks
Result: Suppressed total levodopa-induced dyskinesia (LID) severity significantly compared to vehicle controls on day 5 and day 10 of levodopa treatment.
Reduced peak LID severity significantly compared to vehicle controls on day 10.
Dampened LID severity significantly compared to vehicle controls at the 70-minute post-levodopa peak of LID expression on day 10.
Showed no significant difference in total spine density and thin spine density between dopamine-depleted and intact striatum, unlike vehicle-treated rats.
Prevented the significant increase in mushroom spine density in the dopamine-depleted striatum observed in vehicle-treated dyskinetic rats.
Animal Model: Wistar (male, 220-350 g)
Dosage: 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg
Administration: s.c.
Result: Showed no significant changes in thermonociceptive withdrawal latencies or AUC compared to saline.
Significantly increased mechanonociceptive withdrawal latencies at 30 min and 1 h at 1 mg/kg dose.
Significantly increased mechanonociceptive withdrawal latencies at 30 min and 1 h at 3 mg/kg dose.
Produced significant AUC increases in mechanonociceptive tests at 1 mg/kg and 3 mg/kg doses.
Had its antinociceptive effect at 1 mg/kg completely prevented by co-administration with 0.3 mg/kg raclopride.
Animal Model: Wistar (Hsd: [WI]BR) (male, 150-200 g)
Dosage: 0.01 mg/kg; 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg
Administration: i.p.; 1 hour prior to sacrifice (1 mg/kg); 2 hours prior to sacrifice (2, 3 mg/kg); 4 hours prior to sacrifice (0.01, 0.03, 0.1, 0.3, 1, 3 mg/kg)
Result: Reduced cerebral hemisphere homovanillic acid (HVA) concentration by 13% at 0.03 mg/kg.
Reduced cerebral hemisphere 3,4-dihydroxyphenylacetic acid (DOPAC) concentration by 22% and HVA by 29% at 0.1 mg/kg.
Reduced hypothalamic epinephrine concentration by 41%, cerebral hemisphere DOPAC by 32%, and HVA by 43% at 0.3 mg/kg; left hypothalamic dopamine and norepinephrine concentrations unchanged.
Reduced hypothalamic epinephrine concentration by 53%, cerebral hemisphere DOPAC by 41%, and HVA by 52% at 1 mg/kg; left hypothalamic dopamine and norepinephrine concentrations unchanged.
In a separate experiment, reduced hypothalamic epinephrine by 23%, cerebral hemisphere DOPAC by 36%, and HVA by 48% at 1 mg/kg; these effects were blocked by spiperone pretreatment.
Reduced hypothalamic epinephrine concentration by 35%, hypothalamic norepinephrine by 12%, and increased hypothalamic MHPG sulfate by 85% at 2 mg/kg.
Reduced hypothalamic epinephrine concentration by 41%, cerebral hemisphere DOPAC by 26%, and HVA by 45% at 3 mg/kg; these effects were blocked by spiperone pretreatment.
In another experiment, increased hypothalamic dopamine concentration by 21%, reduced hypothalamic norepinephrine by 16%, and increased brain stem MHPG sulfate by 26% at 3 mg/kg; all these effects were blocked by spiperone pretreatment.
In a third experiment, reduced hypothalamic epinephrine by 40%, increased hypothalamic dopamine by 17%, reduced hypothalamic norepinephrine by 8%, and increased brain stem MHPG sulfate by 65% at 3 mg/kg.
Animal Model: wild-type AB strain (both genders)
Dosage: 5.5 μM; 16.7 μM; 50 μM
Administration: immersion; single 24-hour exposure; at 5 dpf
Result: Increased time spent at the tank bottom in open tank test for 50 μM dose, indicating anxiety-like behavior.
Increased absolute turn angle in open tank test for 16.7 μM dose, indicating elevated erratic movements.
Increased duration and frequency of stereotypic swimming in open tank test across all doses.
Decreased test session latency compared to controls in inhibitory avoidance task.
Caused no significant changes in distance traveled, time mobile, or acceleration across all doses.
Caused no significant differences in social interaction task metrics compared to controls.
Caused no significant differences in aggression test metrics compared to controls.
Animal Model: Macaca mulatta (male, 4-7 years old, 6-12 kg)
Dosage: 7 nmol; 35 nmol; 70 nmol
Administration: bilateral intracerebral infusion into nucleus accumbens core; 0.2 μl/min
Result: Reduced baseline startle amplitude on pulse-alone trial.
Disrupted PPI significantly when collapsed across all doses compared to vehicle/sham.
Disrupted PPI significantly when collapsed across 35 nM and 70 nM doses compared to vehicle/sham, with significant deficits at 8 dB and 12 dB prepulse intensities.
Reduced PPI significantly at 12 dB prepulse intensity alone at 70 nM dose compared to vehicle/sham.
Animal Model: Wistar rats (adult male, 240 g; obsessive-compulsive disorder model via subcutaneous quinpirole injections twice weekly for 5 weeks)
Dosage: 0.5 mg/kg
Administration: s.c.; twice weekly; 5 weeks
Result: Increased marble burying.
Increased self-grooming activity.
Decreased time spent in open arms and decreased open arm entries in the elevated plus maze.
Showed non-significant decrease in head dipping activity in the hole board test.
Increased mRNA expression of interleukin-6 and C-reactive protein in the amygdala, with statistically insignificant increase in tumor-necrosis factor-α.
Increased neuronal nitric oxide synthase levels in the frontal cortex.
Showed non-significant changes in frontal cortex dopamine, noradrenaline, and 5-hydroxytryptamine levels.
Reduced goblet cell count and villus height/crypt depth ratio in the colon.
Decreased fecal levels of acetate, propionate, and butyrate.
Altered gut microbiota composition including increased relative abundance of Allobaculum, Bifidobacterium (specifically Bifidobacterium animalis), and decreased relative abundance of Lactobacillus (including Lactobacillus reuteri and Lactobacillus vaginalis) at the genus and species levels.
Animal Model: C57BL/6J (male, 25-30 g)
Dosage: 2 mM; 4 mM
Administration: intra-PVT microinjection; 0.5 μl total volume over 2 minutes
Result: Shortened emergence time to 182.1 s (4 mM dose) compared to saline control.
Showed no significant effect on emergence time at 2 mM dose (261.3 s) relative to saline.
Did not alter isoflurane induction time at either 2 mM or 4 mM dose relative to saline.
Decreased burst suppression ratio from 42.78% pre-injection to 35.15% post-injection.
Increased mean number of c-Fos-positive nuclei in the PVT to 371.2 per mm2 (4 mM dose) compared to saline control.
性状 固体
颜色 White to off-white

化学信息

分子量 219.33
分子式 C13H21N3
CAS No. 80373-22-4
别名 LY 171555; (-)-LY 141865

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (455.93 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.5593 mL22.7967 mL45.5934 mL113.9835 mL
5 mM0.9119 mL4.5593 mL9.1187 mL22.7967 mL
10 mM0.4559 mL2.2797 mL4.5593 mL11.3983 mL
15 mM0.3040 mL1.5198 mL3.0396 mL7.5989 mL
20 mM0.2280 mL1.1398 mL2.2797 mL5.6992 mL
25 mM0.1824 mL0.9119 mL1.8237 mL4.5593 mL
30 mM0.1520 mL0.7599 mL1.5198 mL3.7994 mL
40 mM0.1140 mL0.5699 mL1.1398 mL2.8496 mL
50 mM0.0912 mL0.4559 mL0.9119 mL2.2797 mL
60 mM0.0760 mL0.3799 mL0.7599 mL1.8997 mL
80 mM0.0570 mL0.2850 mL0.5699 mL1.4248 mL
100 mM0.0456 mL0.2280 mL0.4559 mL1.1398 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础